Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022
Rhea-AI Summary
Alps Group (Nasdaq: ALPS) announced that subsidiary MyGenome has expanded its MS ISO 15189:2022 accreditation to include Whole Genome Sequencing (WGS).
The accreditation validates MyGenome's genomic data accuracy and reliability for clinical and research use and supports access to government-linked healthcare programs, cross-border partnerships, and institutional clients across Southeast Asia.
AI-generated analysis. Not financial advice.
Positive
- MS ISO 15189:2022 accreditation now covers Whole Genome Sequencing
- Positions MyGenome among a select group of Southeast Asian WGS laboratories
- Supports access to government-linked healthcare programs and institutional clients
- Strengthens Alps Group’s clinical-grade genomics infrastructure in Southeast Asia
Negative
- None.
News Market Reaction – ALPS
On the day this news was published, ALPS declined 1.74%, reflecting a mild negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $109.82M at that time.
Data tracked by StockTitan Argus on the day of publication.
MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian Genomics
KUALA LUMPUR, Malaysia, June 09, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its subsidiary, MyGenome Sdn. Bhd. (“MyGenome”), has received accreditation for its Whole Genome Sequencing (“WGS”) under MS ISO 15189:2022.
MS ISO 15189:2022 is an internationally recognized clinical standard that sets rigorous requirements for quality and competence in medical laboratories. Unlike targeted genetic panels, WGS examines a patient's complete DNA sequence, making accreditation at this level a meaningful technical distinction. The expanded accreditation confirms that MyGenome's genomic data meets the accuracy, reproducibility, and reliability benchmarks required for clinical use, healthcare adoption, and integration into research programs, positioning MyGenome among a select group of genomics laboratories in Southeast Asia operating WGS under this standard.
This milestone provides additional validation for institutional partners and investors alike, demonstrating that MyGenome's WGS process meets the compliance-grade infrastructure required for adoption in clinical and research settings, broadening Alps’ addressable market to include government-linked healthcare programs, cross-border partnerships, and institutional clients across the region.
“Expanding our MS ISO 15189:2022 accreditation scope to include Whole Genome Sequencing is a meaningful validation of the clinical infrastructure we are building,” said Dr. Tham Seng Kong, Executive Director and Group Chief Executive Officer of Alps Group Inc. “Accreditation at this level signals to hospitals, research institutions, and partners that our genomic data is globally credible, clinically actionable, and fit for interrogation across our broader ecosystem. This milestone advances our goal of making world-class genomics a reality for patients across Southeast Asia.”
To be added to the Alps Group Inc email distribution list, please email Alps@kcsa.com with ALPS in the subject line.
About Alps Group Inc
Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Philip Carlson
KCSA Strategic Communications
Phone: 212.896.1233
Email: Alps@kcsa.com
